Business
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present a company update and participate in a panel at the 2020 BIO CEO & Investor Conference. The conference takes place February 10-11, 2020 at the New York Marriott Marquis.\n Presentation:Date/Time: Monday, February 10, 2020 at 11:15 a.m. ETLocation: Odets Room, 4th Floor, New York Marriott MarquisWebcast Information: A live webcast of the presentation will be available on http://www.veracast.com/webcasts/bio/ceoinvestor2020/63112233331.cfm. A replay will be available via www.anavex.com and will be accessible for three months following the presentation. Panel:Title: “Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs”Date/Time: Tuesday, February 11, 2020 at 3:00 p.m. ET - 3:55 p.m. ETLocation: Lyceum Complex, 5th Floor, New York Marriott Marquis Attendees are invited to request a one-on-one meeting with Anavex Life Sciences management during the conference through the 1-on-1 partnering system or email [email protected]. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properti...